Streetbeat News

Products Services

XGN

Exagen Inc. (NASDAQ:XGN) and Johns Hopkins University have announced an exclusive license agreement for the development of novel patented biomarkers for therapeutic management of patients with lupus nephritis. Exagen will acquire a worldwide exclusive license to an invention from the laboratory of Michelle Petri, MD, MPH, and Andrea Fava, MD. The company plans to develop these biomarkers into assays to aid diagnostic and treatment decisions.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:26 pm

LYEL

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has received FDA Orphan Drug Designation for LYL845, a product candidate for the treatment of stage IIB-IV melanoma. The designation provides certain incentives, including tax credits for qualified clinical trials and potential seven-year marketing exclusivity upon FDA approval. LYL845 is currently being investigated in a Phase 1 clinical trial in patients with advanced melanoma, non-small cell lung cancer, and colorectal cancer. Initial data from the trial are expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:22 pm

U

Unity Software has announced plans to implement a restructuring strategy within this quarter, which is expected to be completed by the end of Q1 2024. The plan may include discontinuing certain product offerings, reducing the workforce, and downsizing the office footprint.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:21 pm

AAPL

Taylor Swift has been named Apple Music's Artist of the Year, with 65 of her songs dominating Apple Music's Global Daily Top 100 in the first 10 months of the year. Apple Inc's Vice President of Apple Music and Beats, Oliver Schusser, acknowledged Swift's impact on the music industry. Apple Music is now showcasing Swift's musical journey, with her album 'Midnights' being the largest debut by a female artist in Apple Music history.

Portfolio Pulse from Franca Quarneti

November 09, 2023 | 10:15 pm

ENSC

Ensysce Biosciences Inc. is expected to release the clinical study results of PF614-201 by the end of the year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:07 pm

SONY

Sony Group Corp. (NYSE:SONY) has announced that its PS5 exclusive game, Marvel's 'Spider-Man 2', has sold over five million copies within 11 days of its launch, surpassing the record of fastest-selling PlayStation Studios game within a 24-hour period. The game's success outpaced Santa Monica Studio’s 'God of War: Ragnarok', which holds the record for debut week sales with 5.1 million copies. Insomniac, the game's developer, has future plans for a Wolverine game and potential spinoffs.

Portfolio Pulse from Franca Quarneti

November 09, 2023 | 10:04 pm

XENE

Xenon Pharmaceuticals announced that its partner, Neurocrine Biosciences, reported that the Phase 2 clinical trial evaluating NBI-921352 in adult patients with focal onset seizures failed to demonstrate meaningful reduction in seizure frequency. No further development with NBI-921352 in FOS is planned at this time. Xenon intends to work closely with Neurocrine to review the data and understand any potential implications for the second ongoing study with NBI-921352 in SCN8A-developmental epileptic encephalopathy.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:03 pm

USDC

Circle has announced a v2.2 upgrade to USDC and EURC stablecoins, which will include decreased gas costs, better support for account abstraction, and increased security for transactions on EVM blockchains. The upgrade is fully backward compatible and requires no action from developers or users. The efficiency improvements will lead to a 6-7% gas cost reduction for common operations like making a transfer, payment, or trade with USDC or EURC. The rollouts commenced on Nov. 9 and Circle plans to finish the updates in the upcoming months.

Portfolio Pulse from Khyathi Dalal

November 09, 2023 | 9:49 pm

VOR

Vor Bio (NASDAQ:VOR) has presented updated clinical data from its Phase 1/2a study of trem-cel (VOR33) in patients with acute myeloid leukemia (AML). The data shows successful engraftment of trem-cel in all seven patients treated to date. The company also reported hematologic protection in three patients treated with multiple cycles of Mylotarg. Vor Bio's next steps include dose escalation of Mylotarg and providing treatment opportunities for trem-cel patients who become measurable residual disease positive or relapse.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:49 pm

IGT

International Game Technology PLC (IGT) has announced a multi-year agreement with Ponce Plaza Hotel & Casino in Puerto Rico. The casino will use IGT's PlaySports technology and services to power Puerto Rico's first casino brand-led retail and mobile sportsbook, PlayBets by Ponce Plaza.

Portfolio Pulse from Charles Gross

November 09, 2023 | 9:32 pm